Zinc Ion

Zinc Ion

SCHEMBL2507367

CCP(=O)([O-])CCc1ccccc1.CCP(=O)([O-])CCc1ccccc1.[Zn+2]

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CETP P11597 1/20 0.49
TSHR P16473 3/20 0.48
CYP2D6 P10635 1/20 0.43
POLB P06746 1/20 0.42
ATM Q13315 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
ALDH1A1 P00352 3/20 0.39
TP53 P04637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
FDPS P14324 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
CASP1 P29466 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ANPEP P15144 1/20 0.38
ERAP1 Q9NZ08 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20575204 0.96 CETP (0.49) CETPTSHRCYP2D6POLBATM
Zinc Ion SCHEMBL28535952 0.81 TSHR (0.53) CETPTSHRCYP2D6POLBATM
SCHEMBL6229513 0.77 TSHR (0.53) CETPTSHRCYP2D6POLBATM
SCHEMBL28538163 0.77 TSHR (0.53) CETPTSHRCYP2D6POLBATM
Potassium Ion SCHEMBL6232670 0.77 TSHR (0.53) CETPTSHRCYP2D6POLBATM
SCHEMBL2488080 0.76 TSHR (0.69) CETPTSHRCYP2D6POLBALDH1A1
SCHEMBL20575202 0.74 TSHR (0.67) CETPTSHRCYP2D6POLBALDH1A1
SCHEMBL2507365 0.74 TSHR (0.67) CETPTSHRCYP2D6POLBALDH1A1
Zinc Ion SCHEMBL28535948 0.73 TSHR (0.50) TSHRPOLBL3MBTL1MEN1KMT2A
Zinc Ion SCHEMBL28530931 0.72 TSHR (0.53) CETPTSHRALDH1A1L3MBTL1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110245386-A1 Method for the Production of Mixed-Substituted Dialkylphosphinic Acids, Esters, and Salts, and Use Thereof CLARIANT FINANCE (BVI) LIMITED (VG) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245386-A1 Method for the Production of Mixed-Substituted Dialkylphosphinic Acids, Esters, and Salts, and Use Thereof HAO2, ACSL3, SCO2 CETP 807/4885TSHR 852/4885CYP2D6 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.